Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Genetics Investing
Precision Therapeutics Forms TumorGenesis Inc. Subsidiary to Focus on the Next Generation of Patient Derived Tumor Models Genetics Investing
Excellent Cohort A Data From Final Primary Evaluation Period in Cynata GvHD Phase 1 Clinical Trial Genetics Investing
Pluristem’s PLX-R18 Improves Hematopoietic Transplantation as Reported in Scientific Journal Frontiers in Medicine Genetics Investing
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress Genetics Investing
Endocyte and ITM Announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial Genetics Investing
Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results Genetics Investing
Sanofi: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Bioverativ Pharmaceutical Investing
Helix BioPharma Appoints Deloitte as Strategic Advisor to Explore Partnering and Licensing Opportunities Genetics Investing
Primary Endpoint Successfully Achieved in Mesoblast’s Phase 3 Cell Therapy Trial for Acute Graft Versus Host Disease Genetics Investing
G1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights Genetics Investing